[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

GB202113602D0 - Treatment of a disorder affecting an eyelid muscle of a subject - Google Patents

Treatment of a disorder affecting an eyelid muscle of a subject

Info

Publication number
GB202113602D0
GB202113602D0 GBGB2113602.3A GB202113602A GB202113602D0 GB 202113602 D0 GB202113602 D0 GB 202113602D0 GB 202113602 A GB202113602 A GB 202113602A GB 202113602 D0 GB202113602 D0 GB 202113602D0
Authority
GB
United Kingdom
Prior art keywords
subject
treatment
disorder affecting
eyelid muscle
eyelid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2113602.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Biopharm Ltd
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Priority to GBGB2113602.3A priority Critical patent/GB202113602D0/en
Publication of GB202113602D0 publication Critical patent/GB202113602D0/en
Priority to KR1020247012920A priority patent/KR20240067100A/en
Priority to JP2024518109A priority patent/JP2024534541A/en
Priority to AU2022351260A priority patent/AU2022351260A1/en
Priority to CA3228712A priority patent/CA3228712A1/en
Priority to EP22782758.1A priority patent/EP4404955A1/en
Priority to PCT/GB2022/052415 priority patent/WO2023047127A1/en
Ceased legal-status Critical Current

Links

GBGB2113602.3A 2021-09-23 2021-09-23 Treatment of a disorder affecting an eyelid muscle of a subject Ceased GB202113602D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB2113602.3A GB202113602D0 (en) 2021-09-23 2021-09-23 Treatment of a disorder affecting an eyelid muscle of a subject
KR1020247012920A KR20240067100A (en) 2021-09-23 2022-09-23 Modified BONT/A for use in the treatment of disorders affecting the eyelid muscles of a subject
JP2024518109A JP2024534541A (en) 2021-09-23 2022-09-23 Modified BoNT/A for use in treating disorders affecting the eyelid muscles of a subject
AU2022351260A AU2022351260A1 (en) 2021-09-23 2022-09-23 Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject
CA3228712A CA3228712A1 (en) 2021-09-23 2022-09-23 Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject
EP22782758.1A EP4404955A1 (en) 2021-09-23 2022-09-23 Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject
PCT/GB2022/052415 WO2023047127A1 (en) 2021-09-23 2022-09-23 Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2113602.3A GB202113602D0 (en) 2021-09-23 2021-09-23 Treatment of a disorder affecting an eyelid muscle of a subject

Publications (1)

Publication Number Publication Date
GB202113602D0 true GB202113602D0 (en) 2021-11-10

Family

ID=78399523

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2113602.3A Ceased GB202113602D0 (en) 2021-09-23 2021-09-23 Treatment of a disorder affecting an eyelid muscle of a subject

Country Status (1)

Country Link
GB (1) GB202113602D0 (en)

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006204A1 (en) 1990-09-28 1992-04-16 Ixsys, Inc. Surface expression libraries of heteromeric receptors
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO2006027207A1 (en) 2004-09-06 2006-03-16 Toxogen Gmbh Transport protein which is used to introduce chemical compounds into nerve cells
WO2006114308A2 (en) 2005-04-26 2006-11-02 Toxogen Gmbh Carrier for targeting nerve cells
US20070166332A1 (en) 2005-09-19 2007-07-19 Allergan, Inc. Clostridial Toxin Activatable Clostridial Toxins
WO2010120766A1 (en) 2009-04-14 2010-10-21 Mcw Research Foundation, Inc. Engineered botulinum neurotoxin
US20110318385A1 (en) 2010-06-23 2011-12-29 Wisconsin Alumni Research Foundation Engineered botulinum neurotoxin c1 with selective substrate specificity
WO2013180799A1 (en) 2012-05-30 2013-12-05 President And Fellows Of Harvard College Engineered botulinum neurotoxin
WO2015004461A1 (en) 2013-07-09 2015-01-15 Syntaxin Limited Cationic neurotoxins
WO2015166242A1 (en) 2014-04-29 2015-11-05 Ipsen Bioinnovation Limited Manufacture of recombinant clostridium botulinum neurotoxins
WO2016154534A1 (en) 2015-03-26 2016-09-29 President And Fellows Of Harvard College Engineered botulinum neurotoxin
WO2017055274A1 (en) 2015-10-02 2017-04-06 Ipsen Biopharm Limited Method for purifying clostridial neurotoxin
EP2677029B1 (en) 2011-05-19 2017-05-10 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides
WO2017191315A1 (en) 2016-05-05 2017-11-09 Ipsen Biopharm Limited Chimeric neurotoxins
US10087432B2 (en) 2012-11-21 2018-10-02 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1992006204A1 (en) 1990-09-28 1992-04-16 Ixsys, Inc. Surface expression libraries of heteromeric receptors
WO2006027207A1 (en) 2004-09-06 2006-03-16 Toxogen Gmbh Transport protein which is used to introduce chemical compounds into nerve cells
WO2006114308A2 (en) 2005-04-26 2006-11-02 Toxogen Gmbh Carrier for targeting nerve cells
US20070166332A1 (en) 2005-09-19 2007-07-19 Allergan, Inc. Clostridial Toxin Activatable Clostridial Toxins
WO2010120766A1 (en) 2009-04-14 2010-10-21 Mcw Research Foundation, Inc. Engineered botulinum neurotoxin
US20110318385A1 (en) 2010-06-23 2011-12-29 Wisconsin Alumni Research Foundation Engineered botulinum neurotoxin c1 with selective substrate specificity
EP2677029B1 (en) 2011-05-19 2017-05-10 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides
EP2524963B1 (en) 2011-05-19 2018-10-31 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides
WO2013180799A1 (en) 2012-05-30 2013-12-05 President And Fellows Of Harvard College Engineered botulinum neurotoxin
US10087432B2 (en) 2012-11-21 2018-10-02 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides
WO2015004461A1 (en) 2013-07-09 2015-01-15 Syntaxin Limited Cationic neurotoxins
WO2015166242A1 (en) 2014-04-29 2015-11-05 Ipsen Bioinnovation Limited Manufacture of recombinant clostridium botulinum neurotoxins
WO2016154534A1 (en) 2015-03-26 2016-09-29 President And Fellows Of Harvard College Engineered botulinum neurotoxin
WO2017055274A1 (en) 2015-10-02 2017-04-06 Ipsen Biopharm Limited Method for purifying clostridial neurotoxin
WO2017191315A1 (en) 2016-05-05 2017-11-09 Ipsen Biopharm Limited Chimeric neurotoxins

Non-Patent Citations (39)

* Cited by examiner, † Cited by third party
Title
ALTSCHUL ET AL., BULL. MATH. BIO., vol. 48, 1986, pages 603 - 16
AOKI ET AL., EUR. J. NEUROL., vol. 6, 1999, pages S3 - S10
AOKI KR, TOXICON, vol. 39, 2001, pages 1815 - 1820
BOWIESAUER, PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 2152 - 6
BROIDE RSRUBINO JNICHOLSON GS ET AL.: "The rat Digit Abduction Score (DAS) assay: A physiological model for assessing botulinum neurotoxin-induced skeletal muscle paralysis", TOXICON, vol. 71, 2013, pages 18 - 24, XP028595208, DOI: 10.1016/j.toxicon.2013.05.004
C. E. LAWRENCE ET AL.: "Detecting Subtle Sequence Signals: A Gibbs Sampling Strategy for Multiple Alignment", SCIENCE, vol. 262, no. 5131, 1993, pages 208 - 214, XP001152872, DOI: 10.1126/science.8211139
CHADDOCK ET AL.: "Expression and purification of catalytically active, non-toxic endopeptidase derivatives of Clostridium botulinum toxin type A", PROTEIN EXPR. PURIF., 2002
CHUNG ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 10145 - 9
CHUNG ET AL., SCIENCE, vol. 259, 1993, pages 806 - 9
CUNNINGHAMWELLS, SCIENCE, vol. 244, 1989, pages 1081 - 5
DE VOS ET AL., SCIENCE, vol. 255, 1992, pages 306 - 12
DERBYSHIRE ET AL., GENE, vol. 46, 1986, pages 145
ELLMAN ET AL., METHODS ENZYMOL., vol. 202, 1991, pages 301
ERIC DEPIEREUXERNEST FEYTMANS: "Match-Box: A Fundamentally New Algorithm for the Simultaneous Alignment of Several Protein Sequences", CABIOS, vol. 8, no. 5, 1992, pages 501 - 509
HALEMARHAM: "THE HARPER COLLINS DICTIONARY OF BIOLOGY", 1991, HARPER PERENNIAL
HALPERN J, J. BIOL. CHEM., vol. 268, no. 15, 1993, pages 11188 - 11192
HENIKOFFHENIKOFF, PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 10915 - 19
HERREROS J, BIOCHEM. J., vol. 347, 2000, pages 199 - 204
IVO VAN WALLE ET AL.: "Align-M - A New Algorithm for Multiple Alignment of Highly Divergent Sequences", BIOINFORMATICS, vol. 20, no. 9, 2004, pages 1428 - 1435
JULIE D. THOMPSON ET AL.: "CLUSTAL W: Improving the Sensitivity of Progressive Multiple Sequence Alignment Through Sequence Weighting, Position- Specific Gap Penalties and Weight Matrix Choice", NUCLEIC ACIDS RESEARCH, vol. 22, no. 22, 1994, pages 4673 - 4680, XP002956304
KNAPP, AM. CRYST. ASSOC. ABSTRACT PAPERS, vol. 25, 1998, pages 90
KOIDE ET AL., BIOCHEM, vol. 33, 1994, pages 7470 - 6
LACEY DB, NAT. STRUCT. BIOL., vol. 5, 1998, pages 898 - 902
LOWMAN ET AL., BIOCHEM, vol. 30, 1991, pages 10832 - 7
MASUYER ET AL.: "Structure and activity of a functional derivative of Clostridium botulinum neurotoxin B", J. STRUCT. BIOL., 2011
NER ET AL., DNA, vol. 7, 1988, pages 127
OSAMU GOTOH: "Significant Improvement in Accuracy of Multiple Protein. Sequence Alignments by Iterative Refinement as Assessed by Reference to Structural Alignments", J. MOL. BIOL., vol. 264, no. 4, 1996, pages 823 - 838
REIDHAAR-OLSONSAUER, SCIENCE, vol. 241, 1988, pages 53 - 7
ROBERTSON ET AL., J. AM. CHEM. SOC., vol. 113, 1991, pages 2722
RUMMEL A, MOL. MICROBIOL., vol. 51, no. 3, 2004, pages 631 - 643
RUMMEL A, PNAS, vol. 104, 2007, pages 359 - 364
SINGLETON ET AL.: "DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY", 1994, JOHN WILEY AND SONS
SMITH ET AL., J. MOL. BIOL., vol. 224, 1992, pages 899 - 904
SWAMINATHANESWARAMOORTHY, NAT. STRUCT. BIOL., vol. 7, 2000, pages 1751 - 1759
TORII YGOTO YNAKAHIRA S ET AL.: "Comparison of Systemic Toxicity between Botulinum Toxin Subtypes A1 and A2 in Mice and Rats", BASIC CLIN. PHARMACOL. TOXICOL, vol. 116, 2015, pages 524 - 528
TURCATTI ET AL., J. BIOL. CHEM, vol. 271, 1996, pages 19991 - 8
UMLAND TC, NAT. STRUCT. BIOL., vol. 4, 1997, pages 788 - 792
WLODAVER ET AL., FEBS LETT, vol. 309, 1992, pages 59 - 64
WYNNRICHARDS, PROTEIN SCI, vol. 2, 1993, pages 395 - 403

Similar Documents

Publication Publication Date Title
IL290455A (en) Methods of treating psychological and brain disorders
CA212533S (en) Eye massager
GB202113602D0 (en) Treatment of a disorder affecting an eyelid muscle of a subject
GB202206360D0 (en) Treatment of a disorder affecting an eyelid muscle of a subject
IL304729A (en) Methods of treatment with s1p receptor modulators
CA206918S (en) Set of eye shields
IL307205A (en) Perilesional treatment of skin conditions
GB201914516D0 (en) Treatment of eye disease
GB202104282D0 (en) Skin treatment apparatus
GB202016710D0 (en) Treatment of eye conditions
CA203167S (en) Eye massager
EP4240391A4 (en) Treatment of retinal disorders
GB2599225B (en) Muscle stimulation
IL308993A (en) Device for stimulation of eye activity
KR102622048B9 (en) Structure for eye treatment
CA222248S (en) Wearable skin treatment device
EP4121166C0 (en) Therapeutic treatment of chromatinopathies
CA204705S (en) Skin treatment apparatus
CA204706S (en) Skin treatment apparatus
CA204704S (en) Skin treatment apparatus
GB202116774D0 (en) Treatment of pain
CA203219S (en) Muscle massage device
GB202001353D0 (en) Treatment of skin conditions
GB202100566D0 (en) Treatment of brain damage
GB202108994D0 (en) Muscle stimulation

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)